IMS Health (NYSE: RX), the world’s leading provider of market
intelligence to the pharmaceutical and healthcare industries, today
announced that it expects to close the merger providing for its
acquisition by entities created by certain affiliates of TPG Capital,
L.P. (“TPG”) and the CPP Investment Board (“CPPIB”) by the end of
February 2010.
The consummation of the merger remains subject to the satisfaction or
waiver of certain closing conditions set forth in the merger agreement
and discussed in detail in the Definitive Proxy Statement on Schedule
14A filed with the Securities and Exchange Commission by IMS Health on
December 29, 2009.
If the merger closes as expected by the end of February 2010, IMS Health
will not declare a first-quarter 2010 dividend to its stockholders of
record.
Racial disparities found in delayed COVID-19 testing among healthcare workers